Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid LeukemiaRecruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 19, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, BacterialActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 19, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Primary completion
- Nov 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsInsmed Incorporated · Healthy VolunteersNot yet recruitingINSMLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04119687Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the KneePacira Pharmaceuticals, Inc · Osteoarthritis, KneeActive, not recruitingPCRXLead
- Enrollment
- Locked
- Primary completion
- Nov 28, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02293980A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · ccRCCActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02546661Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · Muscle Invasive Bladder CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 18, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02974738A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Advanced Solid TumorsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 12, 2018Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03476681Study of NEO-201 in Solid Tumors Expansion CohortsPrecision Biologics, Inc · Non Small Cell Lung CancerActive, not recruitingDTILLead
- Enrollment
- Locked
- Primary completion
- Jun 17, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid TumorActive, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin LymphomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06333951Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion...Amgen · Thoracic TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Oct 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06360354A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or...Amgen · Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Oct 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg...BeOne Medicines · Chronic Spontaneous UrticariaRecruitingONCLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07377539A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy ParticipantsJazz Pharmaceuticals · Healthy ParticipantsActive, not recruitingJAZZLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT00378105Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaDana-Farber Cancer Institute · Multiple MyelomaActive, not recruitingTAKCollaboratorBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2009Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT00819546RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSRichard Stone, MD · Acute Myeloid LeukemiaActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT01054196Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 /...Weill Medical College of Cornell University · Multiple MyelomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 2021Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02057133A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadEli Lilly and Company · Breast NeoplasmsActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Mar 15, 2021Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02091245Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLDana-Farber Cancer Institute · Relapsed Acute Lymphoblastic Leukemia (ALL)Active, not recruitingKPTIQCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 2018Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 204 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.